Capital Impact Advisors, LLC Crispr Therapeutics Ag Transaction History
Capital Impact Advisors, LLC
- $75.1 Million
- Q1 2024
A detailed history of Capital Impact Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Capital Impact Advisors, LLC holds 7,605 shares of CRSP stock, worth $422,533. This represents 0.69% of its overall portfolio holdings.
Number of Shares
7,605
Previous 14,614
47.96%
Holding current value
$422,533
Previous $914,000
43.33%
% of portfolio
0.69%
Previous 1.23%
Shares
9 transactions
Others Institutions Holding CRSP
# of Institutions
551Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$453 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$435 Million0.11% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$182 Million2.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$182 Million0.16% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$150 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.33B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....